Physician profile
Raena Olsen
NPI 1619993086
$5,796.95
in general payments reported to CMS, 2019-2025
26 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.93 · 2021: $21.20 · 2022: $1,361 · 2023: $1,520 · 2024: $1,395 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,309 · Education: $13.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,309.49 |
| Education | $13.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,543.55 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $469.76 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Intercept Pharmaceuticals, INC. | $468.13 | 2019-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $440.60 | 2022-2025 | Entyvio |
| Janssen Biotech, INC. | $411.37 | 2022-2025 | Stelara, Tremfya, Simponi |
| Phathom Pharmaceuticals, INC. | $327.19 | 2023-2025 | Voquezna |
| Genzyme Corporation | $320.07 | 2022-2025 | |
| Gilead Sciences, INC. | $257.52 | 2023-2025 | |
| Pfizer INC. | $227.23 | 2023-2025 | |
| Ardelyx, INC. | $217.96 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $195.70 | 2022-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $159.21 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $139.38 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $120.10 | 2022 | |
| Celgene Corporation | $101.24 | 2022-2023 | Zeposia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $89.86 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $84.34 | 2022-2024 | Dificid, Zinplava |
| Celltrion USA INC. | $57.46 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $46.46 | 2022-2023 | Sutab, Suflave |
| Ethicon US, LLC | $29.55 | 2022 | |
| Organon LLC | $22.55 | 2023 | Hadlima, Renflexis |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.81 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.39 | 2022 | |
| Aimmune Therapeutics, INC. | $14.66 | 2025 | Zenpep |
| Boston Scientific Corporation | $13.19 | 2024 | Resolution Clip |
| Romark Laboratories, Lc | $4.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raena Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.